Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GLMD
DateTimeSourceHeadlineSymbolCompany
04/04/202422:06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/03/202413:00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/02/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
12/02/202421:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/11/202321:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202321:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/11/202321:32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
01/11/202320:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202313:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202313:30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202321:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
22/09/202321:05PR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202312:30Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
20/09/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/09/202321:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/08/202321:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
09/08/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
02/08/202321:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/07/202315:12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202314:25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
18/07/202314:23Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202314:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
14/07/202314:30PR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/07/202322:08Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
12/07/202322:29Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/07/202313:00PR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/06/202313:41Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:GLMD